Neuropeptide Y5 receptor antagonists

A compound having the structural formula

• or a pharmaceutically acceptable salt thereof, wherein
• a and b are independently 0, 1 or 2, provided that the sum of a and b is 0 to 3;
• Q is
• X is —S—, —C(O)—, —CH(OR8)— or —C(R23)2—;
• R1 is —N(C1-C6 alkyl)(R12);
• R2, R3, R4 and R5 are independently selected from the group consisting of H, C1-C5 straight or branched alkyl, (C3-C12)cycloalkyl, R14—(C3-C12)cycloalkyl, halogen, —OR8, —N(R8)2, —CO2R8 and CF3;
• R6 and R7 are independently selected from the group consisting of H, (C1-C9)alkyl, (C1-C9)alkenyl, hydroxy-(C1-C9)alkyl, amino-(C1-C9)-alkyl, (C1-C9)alkoxy-(C1-C9)alkyl, (C3-C12)cycloalkyl and (C3-C12)-cycloalkyl-(C1-C6)alkyl, or R6 and R7, together with the carbon to which they are attached, form a 3, 4, 5, 6 or 7-membered carbocyclic ring, or a 4, 5, 6 or 7-membered heterocyclic ring, wherein 1, 2 or 3 ring members are independently selected from the group consisting of O, S and N;
• R8 is independently selected from the group consisting of H, (C1-C6)alkyl, (C3-C12)cycloalkyl, R15-aryl and R24-heteroaryl;
• R9 is (C1-C6)alkyl, (C3-C12)cycloalkyl, R15-aryl or R24-heteroaryl;
• R12 is
• wherein q is 1 or 2, and s is 0, 1 or 2;
• R13 is 1 to 3 substituents independently selected from the group consisting of hydrogen, (C1-C6)alkyl, halogen, (C1-C6)alkoxy and CF3;
• R14 is 1 to 3 substituents independently selected from the group consisting of (C1-C6)alkyl, benzyl, R13-aryl and R13-heteroaryl;
• R15 is 1 to 3 substituents independently selected from the group consisting of hydrogen, (C1-C6)alkyl, halo, polyhalo(C1-C6)alkyl, R17O—, —N(R17)2, —S(R17), R17O—(C1-C6)alkyl, (R17)2N—(C1-C6)alkyl, formyl, —C(O)R17, —COOR17, —CON(R17)2, —OC(O)N(R17)2, —N(R17)C(O)N(R17)2, —NR17C(O)R17, —NR17C(O)OR14, R17S(O)—, R17SO2—, R17SO2NR17— and tri(C1-C6)-alkylsilyl;
• R17 is independently selected from the group consisting of H, (C1-C6)alkyl, (C3-C12)cycloalkyl, (C3-C12)cycloalkyl(C1-C6)alkyl, R13-aryl and R13-heteroaryl;
• R18 is independently selected from the group consisting of H, (C1-C6)alkyl, (C3-C12)cycloalkyl, (C3-C12)cycloalkyl-(C1-C6)alkyl, R15-aryl, R24-heteroaryl, —CO2R9, —C(O)N(R8)2, —COR8 and —SO2R9;
• R20 is (C1-C6)alkyl, (C3-C12)cycloalkyl, (C3-C12)cycloalkyl-(C1-C6)alkyl, hydroxy(C1-C6)alkyl, oxo(C1-C6)alkyl or polyhalo(C1-C6)alkyl;
• R23 is independently selected from the group consisting of H, halogen, (C1-C6)alkyl, (C3-C12)cycloalkyl, R15-aryl, and R24-heteroaryl;
• and
• R24 is 1 to 2 substituents independently selected from the group consisting of hydrogen, (C1-C6)alkyl, halo, polyhalo(C1-C6)alkyl, R17O—, —N(R17)2, —S(R17), R17O—(C1-C6)alkyl, (R17)2N—(C1-C6)alkyl, formyl, —C(O)R17, —COOR17, —CON(R17)2, —OC(O)N(R17)2, —N(R17)C(O)N(R17)2, —NR17C(O)R17, —NR17C(O)OR14, R17S(O)—, R17SO2—, R17SO2NR17— and tri(C1-C6)-alkylsilyl.